Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia.

ABSTRACT: Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the accumulation of myeloid blasts in the bone marrow. Despite the availability of potential curative treatments, patients frequently experience unfavorable outcomes. One crucial aspect contributing to relapse is the plasticity of leukemic clones, which enables them to switch between active proliferation and dormancy. The adaptability of AML underscores the need for novel therapies targeting AML-specific proteins. To address this, genome-wide CRISPR screens can be utilized to identify cancer entity-specific vulnerabilities. Leveraging publicly available functional genomics datasets and comparing AML with non-AML cancer cell lines, we identified a significant dependency on the cell cycle-regulating gene MYBL2 in AML.

SUBMITTER: Kuchler S 

PROVIDER: S-EPMC12537973 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature